Applications of canarypox (ALVAC) vectors in human and veterinary vaccination.
This paper presents data derived from safety and efficacy studies of ALVAC-based rabies and feline leukemia virus (FeLV) vaccine candidates in target species. Inoculation of the ALVAC-RG recombinant was well tolerated in all species including humans and very young dogs. Protection induced in dogs against rabies challenge was long-lasting and could be elicited in the face of high levels of maternally-derived neutralizing antibody. Parenteral inoculation of cats with an ALVAC-FeLV recombinant was safe and induced protection against persistent infection following oro-nasal FeLV challenge.
Virogenetics Corporation, Troy, NY.
J
J
Taylor
J
J
Tartaglia
M
M
Rivière
C
C
Duret
B
B
Languet
G
G
Chappuis
E
E
Paoletti
D000328:Adult; D000818:Animals; D018150:Avipoxvirus / Q000235:genetics*; D002415:Cats; D002986:Clinical Trials as Topic / Q000662:veterinary; D005260:Female; D005822:Genetic Vectors; D006801:Humans; D007112:Immunity, Maternally-Acquired; D005256:Leukemia Virus, Feline / Q000276:immunology*; D011247:Pregnancy; D011819:Rabies Vaccines / Q000009:adverse effects / Q000276:immunology; D015682:Retroviridae Proteins, Oncogenic / Q000009:adverse effects / Q000276:immunology; D012449:Safety; D014611:Vaccination / Q000662:veterinary*; D014613:Vaccines, Attenuated; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology
C078788:ALVAC vaccine; D011819:Rabies Vaccines; D015682:Retroviridae Proteins, Oncogenic; D014613:Vaccines, Attenuated; D014765:Viral Vaccines; C045569:feline leukemia virus vaccine